tiprankstipranks
Trending News
More News >
Proteome Sciences PLC (GB:PRM)
LSE:PRM

Proteome Sciences (PRM) Price & Analysis

Compare
2 Followers

PRM Stock Chart & Stats


---

Financials

PRM FAQ

What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 2.22p and its highest was 5.40p in the past 12 months.
    What is Proteome Sciences PLC’s market cap?
    Proteome Sciences PLC’s market cap is £8.09M.
      When is Proteome Sciences PLC’s upcoming earnings report date?
      Proteome Sciences PLC’s upcoming earnings report date is Aug 18, 2025 which is in 106 days.
        How were Proteome Sciences PLC’s earnings last quarter?
        Proteome Sciences PLC released its earnings results on Apr 10, 2025. The company reported -0.004p earnings per share for the quarter, missing the consensus estimate of N/A by -0.004p.
          Is Proteome Sciences PLC overvalued?
          According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Proteome Sciences PLC pay dividends?
            Proteome Sciences PLC does not currently pay dividends.
            What is Proteome Sciences PLC’s EPS estimate?
            Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Proteome Sciences PLC have?
            Proteome Sciences PLC has 295,182,040 shares outstanding.
              What happened to Proteome Sciences PLC’s price movement after its last earnings report?
              Proteome Sciences PLC reported an EPS of -0.004p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.211%.
                Which hedge fund is a major shareholder of Proteome Sciences PLC?
                Currently, no hedge funds are holding shares in GB:PRM
                ---

                Company Description

                Proteome Sciences PLC

                Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Bioventix
                Genedrive
                N4 Pharma
                Oxford BioMedica
                Abingdon Health PLC
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis